Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/4/2025

Proteus mirabilis UTI Management

  • The European Association of Urology recommends fluoroquinolones, trimethoprim-sulfamethoxazole, and third-generation cephalosporins for uncomplicated UTIs caused by P. mirabilis, when local resistance is <10% 1, 2
  • For complicated UTIs involving P. mirabilis, the European Association of Urology recommends amoxicillin plus an aminoglycoside, second-generation cephalosporin plus an aminoglycoside, and intravenous third-generation cephalosporin 3

Epidemiology and Characteristics

  • P. mirabilis is a common uropathogen found in cultures, particularly in complicated UTIs, according to the European Association of Urology 1, 4
  • P. mirabilis is a urease-producing bacterium that can lead to stone formation in the urinary tract, as stated by the European Association of Urology 5

Clinical Implications and Management

  • The European Association of Urology recommends that urine culture and susceptibility testing should always be performed when P. mirabilis is suspected, and initial empiric therapy should be tailored based on local resistance patterns 1, 3
  • Treatment duration for P. mirabilis UTIs generally ranges from 7-14 days, according to the European Association of Urology 1